Evidence for a synergistic effect of somatostatin on vasoactive intestinal polypeptide-induced prolactin release in the rat: comparison with its effect on thyrotropin (TSH)-releasing hormone-stimulated TSH release.

Michalkiewicz M, Suzuki M, Kato M

Endocrinology1 Jul 1987Cited by 4 (Europe PMC)

PMID2885177DOI10.1210/endo-121-1-371PepBankPUB-02885177

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In anaesthetised male rats, electrical stimulation of the hypothalamic periventricular nucleus significantly enhanced VIP-induced PRL release.
In plain wordsIn rats, electrical stimulation of a brain area increased the prolactin release that VIP caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP-induced PRL release with periventricular nucleus stimulation
Study
ratn: not reported in source
Pentobarbital-anesthetized male rats with atrial cannulae
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
Electrical stimulation of the PE significantly enhanced VIP-induced PRL release 19 min after the bolus injection of VIP (from 29.3 +/- 7.2 to 59.7 +/- 14.9 ng/ml, P less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of electrical stimulation of the hypothalamic periventricular nucleus (PE) on vasoactive intestinal polypeptide (VIP)-induced PRL and TRH-stimulated TSH secretion were studied using pentobarbital-anesthetized male rats bearing indwelling cannulae in the right atria.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0288517701
02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In anaesthetised male rats, a bolus injection of somatostatin increased the PRL response to VIP.
In plain wordsIn rats, a single somatostatin injection increased the prolactin release that VIP caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP-induced PRL release with somatostatin bolus
Study
ratn: not reported in source
Pentobarbital-anesthetized male rats with atrial cannulae
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
A bolus injection of SRIF had a similar effect and increased the PRL response to VIP (from 29.3 +/- 7.2 to 114.7 +/- 22.4 ng/ml, P less than 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of electrical stimulation of the hypothalamic periventricular nucleus (PE) on vasoactive intestinal polypeptide (VIP)-induced PRL and TRH-stimulated TSH secretion were studied using pentobarbital-anesthetized male rats bearing indwelling cannulae in the right atria.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0288517702
03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In anaesthetised male rats, continuous infusion of somatostatin did not decrease the stimulatory effect of VIP on PRL release and significantly increased the response to a first VIP injection.
In plain wordsIn rats, a steady somatostatin infusion did not reduce, and instead increased, the prolactin release that VIP caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP-induced PRL release with continuous somatostatin infusion
Study
ratn: not reported in source
Pentobarbital-anesthetized male rats with atrial cannulae
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
Continuous infusion of SRIF did not decrease the stimulatory effect of VIP on PRL release; on the contrary it significantly increased the PRL response to a first VIP injection (10 min after the onset of SRIF-14 infusion) over that observed after a second administration of VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of electrical stimulation of the hypothalamic periventricular nucleus (PE) on vasoactive intestinal polypeptide (VIP)-induced PRL and TRH-stimulated TSH secretion were studied using pentobarbital-anesthetized male rats bearing indwelling cannulae in the right atria.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0288517703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.